Pulichser:
|
May 2022 |
Pages: 120 |
IMR 2482 |
The global diabetic retinopathy market size is expected to reach USD 13.8 billion by 2030 registering a CAGR of 6.4%. The incidence rate of diabetes has been increasing dramatically. According to the International Diabetes Federation, in 2021 there were about 537 million diabetic cases, which is projected to rise to 643 million by 2030 and 783 million by 2045. Diabetes is among the leading cause of blindness in people. Blindness is caused due to leaking or rupturing of retinal blood vessels, which may be permanent or temporary in nature depending on the disease stage. Studies suggest that in 2020 the number of diabetic retinopathy cases were about 103.12 million; the cases are expected to reach 160.5 million by 2045.
Rising patient awareness levels and increasing healthcare expenditure are also among the factors which are likely to propel market growth. Moreover, the increasing geriatric population in both developed and developing nations is expected to propel the market over the forecast period. According to the Population Reference Bureau report titled "Aging in the United States”, the number of people in the U.S. aged 65 years and over was projected to increase from around 46 million in 2016 to over 98 million by 2060. Early detection and treatment guidelines for diabetic retinopathy had significantly reduced due to the COVID-19 pandemic-related constraints. When compared to 2019, intravitreal injections for diabetic retinopathy had decreased significantly globally throughout the pandemic, ranging from around 30 to over 100 percent reduction. However, now that the lockdown restrictions have been removed, the market is expected to grow at a significant rate.
Diabetic Retinopathy Market Report Highlights
The non-proliferative diabetic retinopathy segment accounted for the largest revenue share, by type, in 2021. The presence of a large number of patients within the bracket of fewer than 10 years of diabetic history contributed to the large size of this segment
The anti-VEGF segment accounted for the largest revenue share, by management, in 2021. The high applicability of these drugs in the treatment and early diagnosis of mild to moderate cases of non-proliferative DR treatment is among the prime factors leading to segmental growth
In Asia Pacific, the market is expected to witness the highest CAGR over the forecast period. The large population base in this region, high prevalence of diabetes, and rising geriatric population are likely to bolster the market
Diabetic Retinopathy Market Segmentation
Grand View Research has segmented the global diabetic retinopathy market based on type, management, and region:
Diabetic Retinopathy Type Outlook (Revenue, USD Million, 2018 - 2030)
Proliferative diabetic retinopathy
Non-proliferative diabetic retinopathy
Diabetic Retinopathy Management Outlook (Revenue, USD Million, 2018 - 2030)
Anti-VEGF
Intraocular steroid injection
Laser surgery
Vitrectomy
Diabetic Retinopathy Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
Japan
China
India
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East and Africa
South Africa
Saudi Arabia
UAE
List of Key Players of Diabetic Retinopathy Market
Bayer AG
Allergan plc
Novartis AG
Oxurion NV
Sirnaomics Inc.
Genentech
Alimera Sciences
Ampio Pharmaceuticals
BCN Peptides
Kowa Company, Ltd.
Table of Contents
Chapter 1 Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Type
1.1.2. Management
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2 Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Management outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3 Diabetic Retinopathy Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Increasing prevalence of diabetes
3.4.1.2. Growing geriatric population
3.4.1.3. Increasing prevalence of blindness due to diabetes
3.4.2. Market restraint analysis
3.4.2.1. Lack of accurate diagnosis
3.4.2.2. Adverse effects on treatment
3.5. Diabetic Retinopathy Market Analysis Tools
3.5.1. Industry Analysis - Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. Major Deals & Strategic Alliances Analysis
3.5.4. Market Entry Strategies
Chapter 4 Diabetic Retinopathy Market: Type Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Proliferative Diabetic retinopathy
4.1.2. Non-proliferative diabetic retinopathy
4.2. Type Market Share, 2018 & 2030
4.3. Segment Dashboard
4.4. Global Diabetic Retinopathy Market by Type Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5.1. Proliferative Diabetic retinopathy
4.5.2. Non-proliferative diabetic retinopathy
Chapter 5 Diabetic Retinopathy Market: Management Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Anti-VEGF
5.1.2. Intraocular Steroid Injection
5.1.3. Laser Surgery
5.1.4. Vitrectomy
5.2. Management Market Share, 2018 & 2030
5.3. Segment Dashboard
5.4. Diabetic Retinopathy Market by Management Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5.1. Anti-VEGF
5.5.1.1. Anti- VEGF estimates and forecast 2018 to 2030 (USD Million)
5.5.2. Intraocular Steroid Injection
5.5.2.1. Intraocular steroid injection estimates and forecast 2018 to 2030 (USD Million)
5.5.3. Laser Surgery
5.5.3.1. Laser Surgery market estimates and forecast 2018 to 2030 (USD Million)
5.5.4. Vitrectomy
5.5.4.1. Vitrectomy market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6 Diabetic Retinopathy Market: Regional Estimates & Trend Analysis
6.1. Regional market share analysis, 2018 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Regional Market Share and Leading Players, 2018
6.4.1. North America
6.4.2. Europe
6.4.3. Asia Pacific
6.4.4. Latin America
6.4.5. Middle East and Africa
6.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
6.5.1. North America
6.5.2. Europe
6.5.3. Asia Pacific
6.5.4. Latin America
6.5.5. Middle East and Africa
6.6. Market Size, & Forecasts, Volume and Trend Analysis, 2018 to 2030:
6.7. North America
6.7.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.7.2. U.S.
6.7.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.7.3. Canada
6.7.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.8. Europe
6.8.1. U.K.
6.8.1.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.8.2. Germany
6.8.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.8.3. France
6.8.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.8.4. Italy
6.8.4.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.8.5. Spain
6.8.5.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.9. Asia Pacific
6.9.1. Japan
6.9.1.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.9.2. China
6.9.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.9.3. India
6.9.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.9.4. South Korea
6.9.4.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.9.5. Thailand
6.9.5.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.10. Latin America
6.10.1. Brazil
6.10.1.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.10.2. Mexico
6.10.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.10.3. Argentina
6.10.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.10.4. Colombia
6.10.4.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.11. MEA
6.11.1. Saudi Arabia
6.11.1.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.11.2. South Africa
6.11.2.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
6.11.3. UAE
6.11.3.1. Market estimates and forecast, 2018 - 2030 (Value & Volume)
Chapter 7 Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.2.1. Innovators
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2018
7.3.4. Bayer AG
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Modality benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Allergan plc
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Modality benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Novartis AG
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Modality benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Oxurion NV
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Modality benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Sirnaomics, Inc.
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Modality benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Genetech
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Modality benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Alimera Sciences
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Modality benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Ampio Pharmaceuticals
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Modality benchmarking
7.3.11.4. Strategic initiatives
7.3.12. BNC Peptides
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Modality benchmarking
7.3.12.4. Strategic initiatives
7.3.13. Kowa Company, Ltd.
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Modality benchmarking
7.3.13.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America Diabetic Retinopathy market, by region, 2018 - 2030 (USD million)
Table 3 North America Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 4 North America Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 5 U.S. Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 6 U.S. Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 7 Canada Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 8 Canada Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 9 Europe Diabetic Retinopathy market, by region, 2018 - 2030 (USD million)
Table 10 Europe Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 11 Europe Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 12 U.K. Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 13 U.K. Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 14 Germany Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 15 Germany Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 16 France Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 17 France Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 18 Italy Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 19 Italy Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 20 Spain Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 21 Spain Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 22 Asia Pacific Diabetic Retinopathy market, by region, 2018 - 2030 (USD million)
Table 23 Asia Pacific Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 24 Asia Pacific Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 25 China Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 26 China Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 27 Japan Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 28 Japan Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 29 India Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 30 India Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 31 South Korea Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 32 South Korea Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 33 Thailand Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 34 Thailand Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 35 Latin America Diabetic Retinopathy market, by region, 2018 - 2030 (USD million)
Table 36 Latin America Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 37 Latin America Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 38 Brazil Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 39 Brazil Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 40 Mexico Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 41 Mexico Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 42 Argentina Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 43 Argentina Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 44 Colombia Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 45 Colombia Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 46 Middle East & Africa Diabetic Retinopathy market, by region, 2018 - 2030 (USD million)
Table 47 Middle East & Africa self-monitoring devices market, by Type, 2018 - 2030 (USD million)
Table 48 Middle East & Africa Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 49 South Africa Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 50 South Africa Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 51 Saudi Arabia Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 52 Saudi Arabia Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
Table 53 UAE Diabetic Retinopathy market, by Type, 2018 - 2030 (USD million)
Table 54 UAE Diabetic Retinopathy market, by Management, 2018 - 2030 (USD million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Diabetic Retinopathy market: market outlook
Fig. 14 Diabetic Retinopathy market competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Diabetic Retinopathy market driver impact
Fig. 20 Diabetic Retinopathy market restraint impact
Fig. 21 Diabetic Retinopathy market strategic initiatives analysis
Fig. 22 Diabetic Retinopathy market: Type movement analysis
Fig. 23 Diabetic Retinopathy market: Type outlook and key takeaways
Fig. 24 Proliferating diabetic retinopathy market estimates and forecast, 2018 - 2030
Fig. 25 Non-proliferative diabetic retinopathy market estimates and forecast, 2018 - 2030
Fig. 26 Diabetic Retinopathy market: Management movement analysis
Fig. 27 Diabetic Retinopathy market: Management outlook and key takeaways
Fig. 28 Anti VEGF therapy market estimates and forecast, 2018 - 2030
Fig. 29 Intraocular Steroid Injection market estimates and forecast, 2018 - 2030
Fig. 30 Laser surgery market estimates and forecast, 2018 - 2030
Fig. 31 Vitrectomy market estimates and forecast, 2018 - 2030
Fig. 32 Global Diabetic Retinopathy market: regional movement analysis
Fig. 33 Global Diabetic Retinopathy market: regional outlook and key takeaways
Fig. 34 Global market share and leading players
Fig. 35 North America market share and leading players
Fig. 36 Europe market share and leading players
Fig. 37 Asia Pacific market share and leading players
Fig. 38 Latin America market share and leading players
Fig. 39 Middle East & Africa market share and leading players
Fig. 40 North America: SWOT
Fig. 41 Europe SWOT
Fig. 42 Asia Pacific SWOT
Fig. 43 Latin America SWOT
Fig. 44 MEA SWOT
Fig. 45 North America, by country
Fig. 46 North America
Fig. 47 North America market estimates and forecast, 2018 - 2030
Fig. 48 U.S.
Fig. 49 U.S. market estimates and forecast, 2018 - 2030
Fig. 50 Canada
Fig. 51 Canada market estimates and forecast, 2018 - 2030
Fig. 52 Europe
Fig. 53 Europe market estimates and forecast, 2018 - 2030
Fig. 54 U.K.
Fig. 55 U.K. market estimates and forecast, 2018 - 2030
Fig. 56 Germany
Fig. 57 Germany market estimates and forecast, 2018 - 2030
Fig. 58 France
Fig. 59 France market estimates and forecast, 2018 - 2030
Fig. 60 Italy
Fig. 61 Italy market estimates and forecast, 2018 - 2030
Fig. 62 Spain
Fig. 63 Spain market estimates and forecast, 2018 - 2030
Fig. 64 Asia Pacific
Fig. 65 Asia Pacific market estimates and forecast, 2018 - 2030
Fig. 66 Japan
Fig. 67 Japan market estimates and forecast, 2018 - 2030
Fig. 68 China
Fig. 69 China market estimates and forecast, 2018 - 2030
Fig. 70 India
Fig. 71 India market estimates and forecast, 2018 - 2030
Fig. 72 Thailand
Fig. 73 Thailand market estimates and forecast, 2018 - 2030
Fig. 74 South Korea
Fig. 75 South Korea market estimates and forecast, 2018 - 2030
Fig. 76 Latin America
Fig. 77 Latin America market estimates and forecast, 2018 - 2030
Fig. 78 Brazil
Fig. 79 Brazil market estimates and forecast, 2018 - 2030
Fig. 80 Mexico
Fig. 81 Mexico market estimates and forecast, 2018 - 2030
Fig. 82 Argentina
Fig. 83 Argentina market estimates and forecast, 2018 - 2030
Fig. 84 Colombia
Fig. 85 Colombia market estimates and forecast, 2018 - 2030
Fig. 86 Middle East and Africa
Fig. 87 Middle East and Africa market estimates and forecast, 2018 - 2030
Fig. 88 South Africa
Fig. 89 South Africa market estimates and forecast, 2018 - 2030
Fig. 90 Saudi Arabia
Fig. 91 Saudi Arabia market estimates and forecast, 2018 - 2030
Fig. 92 UAE
Fig. 93 UAE market estimates and forecast, 2018 - 2030
Fig. 94 Participant categorization - Diabetic Retinopathy market
Fig. 95 Market share of key market players - Diabetic Retinopathy market
Get Discount